Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study
Top Cited Papers
- 16 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 35 (1), 62-74
- https://doi.org/10.1038/s41375-020-0773-5
Abstract
Talacotuzumab, a humanized anti-CD123 monoclonal antibody, was evaluated in combination with decitabine in elderly patients with acute myeloid leukemia (AML) not eligible for intensive chemotherapy. A multicenter, phase 2/3 study was initiated to determine the recommended phase 2 dose (RP2D) of talacotuzumab (Part A) followed by an open-label, randomized comparison of talacotuzumab in combination with decitabine versus decitabine alone to assess achievement of complete response (CR) and overall survival (OS) in Part B. Ten patients were enrolled in Part A and 316 in Part B; the results presented here are based on a database lock on January 25, 2018. Part A confirmed the RP2D of talacotuzumab to be 9 mg/kg. In Part B, CR was achieved in 12/80 (15%) patients receiving combination therapy and in 9/82 (11%) patients receiving decitabine alone (odds ratio: 1.4; 95% confidence interval [CI]: 0.6–3.6; p = 0.44). Median (95% CI) OS was 5.36 (4.27–7.95) months for combination therapy versus 7.26 (6.47–8.64) months for decitabine alone (hazard ratio: 1.04; 95% CI: 0.79–1.37; p = 0.78). Combination therapy showed no improvement in efficacy versus decitabine alone, resulting in the Independent Data Monitoring Committee’s recommendation of early termination of enrollment and discontinuation of talacotuzumab treatment.Funding Information
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
- Janssen Research and Development
This publication has 21 references indexed in Scilit:
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemiaBlood, 2019
- CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remissionBlood Cancer Journal, 2017
- Leukemic stem cells: identification and clinical applicationInternational Journal of Hematology, 2017
- Therapeutic targeting of acute myeloid leukemia stem cellsBlood, 2017
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagyCancer, 2011
- Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemiaBlood, 2010
- Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem CellsCell Stem Cell, 2009
- Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategiesEuropean Journal of Haematology, 2004
- The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cellsLeukemia, 2000